Current stock page

Stock Analysis

Ocular Therapeutix, Inc. (OCUL) Stock Analysis

Ocular Therapeutix, Inc. (OCUL) stock analysis covering valuation, fundamentals, technical indicators, risk, AIQ Momentum, analyst catalysts, dividends, and the current AIQ Score.

OCUL Stock Analysis Summary

Ocular Therapeutix, Inc. (OCUL) currently has an AIQ Score of 38/100, indicating a bearish setup. Quality is the strongest factor at 42/100. Momentum is the weakest current factor at 34/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.

Updated Nov 13, 2026 · Market-close data

OCUL at a Glance

Crawlable current metrics from the latest market-close stock snapshot.

MetricCurrent
Price$6.21
AIQ Score38/100
Overall ViewBearish
Technical Analysis ConsensusStrong Sell
Market Cap$1.4B
P/E Ratio (TTM)-4.25
Forward P/E—
EPS (Q3 FY2026)-$0.42
Revenue (Q3 FY2026)$12.87M
Dividend Yield (TTM)0.00%
Beta1.39
Volume2.49M
52-week range$6.00-$16.44
RSI 1437.62
50-Day SMA$7.99
200-Day SMA$8.91
Analyst Price Target$14.00
Next EarningsFeb 4, 2027
As of Nov 13, 2026 · Market close

OCULOcular Therapeutix, Inc.

Healthcare / Biotechnology

Low Priority

Relative Laggard

BearishEdge 1/10
$6.21−$0.07 (−1.11%)

Latest quote

  • Momentum
    34
  • Value
    41
  • Quality
    42
  • Risk resilience
    36
  • Sentiment
    —
algovestiq.comScore data as of Nov 13, 2026

OCUL Stock Analysis Summary

Ocular Therapeutix, Inc. (OCUL) currently has an AIQ Score of 38/100, indicating a bearish setup. Quality is the strongest factor at 42/100. Momentum is the weakest current factor at 34/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.

Updated Nov 13, 2026 · Market-close data
AIQ Composite Posture: Bearish

In a bearish regime, OCUL has AIQ Score of 38/100 with Quality base of 42/100 and fading Momentum at 34/100. Wait for component alignment before adding exposure.

Healthcare · -1.11% stock move · OCUL classified in Biotechnology.

Current Evidence

BearishOCUL is in a bearish AIQ regime; Quality is the strongest visible factor at 42/100.
Core coverage reflects visible evidence only

AlgovestIQ Evidence Summary

Current consensus, supporting evidence, recent changes, and what would strengthen or weaken the view.

Is OCUL Bullish or Bearish Right Now?

OCUL currently has a bearish overall setup. Quality is the strongest factor at 42/100, while Momentum is weakest at 34/100. The current evidence suggests a bearish setup.

Bull Case
  • - Analyst target implies +125.44% upside from the latest quote.
Bear Case
  • - Value is the current constraint at 41/100.
  • - Momentum is weak at 34/100.
  • - Risk Resilience is weak at 36/100.
  • - Price is -30.27% below its 200-day SMA.
  • - Technical consensus has more sell votes than buy votes (36 vs 6).

Current Consensus

OCUL's Technical Analysis Consensus is currently Strong Sell, with 6 buy, 4 neutral, and 36 sell votes. OCUL's 14-day RSI is 37.62, which places the stock in a weaker momentum range. OCUL's beta is 1.39, indicating greater market sensitivity than the broad market.

Signal Confidence
High agreement

What Changed in OCUL?

The largest recent change in OCUL is Momentum moving down by 6.0 points over the available 7-day comparison window. Quality remains the strongest visible factor.

AIQ Score
-3.0
Momentum
-6.0
Quality
-2.0
Risk
+0.0

What Would Change the OCUL Outlook?

The current bearish outlook could improve if AIQ reaches 65 (Bullish), momentum recovers, earnings revisions strengthen, and price confirms a stronger trend above the 50-day and 200-day moving averages. It would weaken if AIQ falls below 50 (Bearish), price loses long-term moving-average support, analyst expectations deteriorate, or risk evidence worsens.

Bullish confirmation

AIQ 65+ (Bullish), RSI above 55, price above SMA-50/SMA-200, and positive catalyst or estimate-revision evidence.

Bearish deterioration

AIQ below 50 (Bearish), RSI below 45, loss of SMA-200, negative revisions, or rising volatility and drawdown risk.

OCUL Decision Framework

Public evidence layers, setup checks, and risk context for Ocular Therapeutix, Inc..

Ocular Therapeutix, Inc. (OCUL) Stock Analysis

Ocular Therapeutix, Inc. has an AIQ Score of 38/100 in a Bearish regime. Quality is strongest at 42/100. Beta is 1.39, above market sensitivity. Review the supporting stock factors together before drawing a conclusion from any single score.

Evidence LayerPublic Evidence
Regime ContextOCUL is in a Bearish AIQ regime with score 38/100.
Signal ConflictThe primary conflict is that quality leads at 42/100 while momentum lags at 34/100.
Factor EvidenceMomentum 34/100 · Value 41/100 · Quality 42/100 · Risk 36/100
PersistenceCurrent snapshot evidence is shown; historical persistence remains in AIQ Pro.

Current Setup Checklist

Factor strengthFail

Quality is the strongest factor at 42/100.

TimingFail

Momentum is 34/100 and RSI (14) is 37.6.

Regime fitFail

OCUL is in a Bearish regime at 38/100.

Risk controlFail

Risk factor is 36/100 with beta 1.39 and annual volatility 76.1%.

ConflictPass

Current conflict: quality leads at 42/100 while momentum lags at 34/100.

AIQ Score
38/100
Price
$6.21
Beta
1.39
RSI (14)
37.6

OCUL Research Cluster

Ticker-specific paths for valuation, technical analysis, catalysts, dividends, financials, risk, and news.

OCUL Fundamentals

OCUL valuation, profitability, growth, margins, balance-sheet strength, and free cash flow.

Revenue
$12.87M
Net income
-$94.78M
Free cash flow
-$68.65M
View full OCUL fundamental analysis

OCUL Technical Analysis

OCUL technical setup based on RSI, MACD, moving averages, AIQ Momentum, volume, trend, volatility, and pivots.

Technical Analysis Consensus
Strong Sell
RSI 14
37.62
Price vs SMA-50
-22.31%
View full OCUL technical analysis

OCUL Stock Catalysts

Track OCUL earnings, analyst ratings, price targets, estimate revisions, stock news, and upcoming events.

Next earnings
Feb 4, 2027
Analyst target
$14.00
News items
5
View OCUL earnings and stock catalysts

OCUL Dividend Analysis

OCUL dividend yield, annual dividend, payout ratio, payment history, and income reliability context.

Dividend yield
0.00%
Annual dividend
—
Payout ratio
—
View OCUL dividend history and analysis

OCUL Financial Data

OCUL revenue, earnings, income statement, balance sheet, cash flow, valuation ratios, and stock metrics.

Quarter revenue
$12.87M
EPS
-$0.42
Periods
8
View OCUL financials

OCUL Risk Analysis

OCUL volatility, beta, drawdown, Sharpe ratio, VaR, and downside resilience.

Beta
1.39
Risk score
36/100
1Y volatility
76.10%
View OCUL risk analysis

OCUL Stock News

OCUL stock news, market tone, recent headlines, and catalyst context.

News items
5
Updated
Nov 15, 2026
Sentiment
—
Read OCUL stock news

OCUL vs Biotechnology Peers

Current peer cohort: OCUL · OMER · ONC · ORKA · PCVX. Compare AIQ, factor scores, Sharpe ratio and 1-year volatility in one indexable view.

PeerAIQValueMomentumRiskSharpe1Y VolatilityCompare
OCUL
Current stock
38/10041/10034/10036/100-0.4576.10%Current
OMER
Omeros Corporation
64/10073/10079/10033/1001.36110.84%OCUL vs OMER
ONC
BeOne Medicines AG
80/10071/10091/10072/1000.4234.16%OCUL vs ONC
ORKA
Oruka Therapeutics, Inc.
77/100—81/10053/1002.2969.09%OCUL vs ORKA
PCVX
Vaxcyte, Inc.
66/100—81/10053/1000.7956.19%OCUL vs PCVX
Pairwise Compare links: OMER · ONC · ORKA · PCVXOCUL vs OMEROCUL vs ONCOCUL vs ORKAOCUL vs PCVXCompare cohort

Peer cohort is resolved dynamically from the AlgovestIQ universe taxonomy and Compare relationship graph. Data as of Nov 13, 2026.

About the AIQ Score

Methodology for the current stock evidence.

As of Nov 13, 2026 · Market close

The AlgovestIQ AIQ Score combines multiple dimensions of stock evidence, including momentum, valuation exposure, quality, risk resilience, sentiment context, and timing signals. It is a descriptive research score, not a guarantee of future performance or a personalized recommendation.

View AIQ methodology

Factor Diagnostics

A compact bridge from the AIQ score to the evidence tabs.

Calculator
Calculate a OCUL stock return scenario

Open the return calculator with stock context while purchase price, shares, dates and fees remain user inputs.

Calculate stock return

Also for OCUL: historical return with reinvested dividends and stock average calculator for several buys.

AIQ Component Profile

Compare the five component scores on one consistent 0–100 scale.

Catalyst preview

Review earnings timing, revisions, news pressure, and prior event reactions in one place.

Open catalysts
Quarterly evidence

8 recent quarterly periods are available for review.

Checked Nov 16, 2026

AIQ Pro

Explore factor drivers, conflicts, persistence, and scenario sensitivity in the advanced workspace.

Fundamentals Verdict

Current snapshot fields are separate from reported-quarter statement tables.

Current TTM P/E
-4.25
As of Nov 13, 2026
Revenue growth
-11.48%
Gross margin
87.32%
Current debt / equity
0.18
Latest quarterly evidence

Latest period Sep 30, 2026.

Review fundamentals
Quarter revenue
$12.87M
Quarter net income
-$94.78M
Quarter free cash flow
-$68.65M

Market Confirmation

Technicals are summarized first, with the indicator library behind it.

Trend
Bearish
Momentum
Mixed
RSI 14
37.62
MACD
-0.37

Risk Alignment

Higher resilience is stronger; exposure metrics stay separate.

Resilience
36/100
Beta
1.39
Annual volatility
76.10%
Max drawdown
-61.45%

OCUL Stock FAQ

What is OCUL stock price today?

Ocular Therapeutix, Inc.'s current stock price is $6.21. Use the live quote with AIQ Score, news, and risk context rather than treating price alone as a decision signal.

Is OCUL bullish or bearish right now?

OCUL's bullish or bearish read depends on the current AIQ Score, factor alignment, technical analysis consensus, valuation, risk, and catalyst evidence. A mixed setup should be treated differently from a broad confirmation across those signals.

What is OCUL's market cap?

OCUL's market cap is $1.4B based on the latest completed market-close snapshot from Nov 13, 2026. Use it with P/E ratio, revenue, and growth metrics to frame company size, valuation, and peer comparisons.

What is OCUL's current P/E ratio?

OCUL's current P/E ratio is -4.25 based on the latest completed market-close snapshot from Nov 13, 2026. Read it with revenue growth, margins, EPS, cash flow, and peer valuation rather than using P/E alone.

What is OCUL's RSI?

OCUL's 14-day RSI is 37.62 based on the latest completed market-close snapshot from Nov 13, 2026. RSI should be interpreted with MACD, moving averages, volume, volatility, and price trend.

Is OCUL above its 50-day and 200-day moving averages?

OCUL is -22.31% from its 50-day SMA and -30.27% from its 200-day SMA based on the latest completed market-close snapshot from Nov 13, 2026. Moving-average position should be read with momentum and broader AIQ evidence.

When is OCUL's next earnings date?

OCUL's next earnings date is currently listed as Feb 4, 2027. Earnings can reset revenue, EPS, price target, analyst rating, and catalyst expectations.

Does OCUL pay a dividend?

OCUL's dividend yield is 0.00% based on the latest completed market-close snapshot from Nov 13, 2026. Dividend yield should be read with payout ratio, free cash flow, growth, and balance-sheet strength.